Lucat1 — a molecule that helps aggressive glioblastoma grow and resist treatment
lncRNA regulation of glioblastoma progression and therapeutic resistance
This work looks at how the molecule Lucat1 helps glioblastoma stem cells survive low-oxygen tumor areas and resist radiation, aiming to point toward ways to make treatments work better for people with aggressive brain tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11235166 on NIH RePORTER |
What this research studies
Researchers will study tumor samples and glioma stem-like cells to see how Lucat1 activates hypoxia-related HIF1 signaling in difficult-to-treat tumor regions. They will use gene-editing and molecular tools to reduce Lucat1 activity in lab-grown cells and test the effects on stem cell survival, growth, and response to radiation. Experiments will include tumor models in animals to see whether lowering Lucat1 slows tumor progression and decreases resistance. Together these approaches are meant to reveal whether Lucat1 is a promising target for future therapies aimed at reducing recurrence.
Who could benefit from this research
Good fit: People with glioblastoma—especially the aggressive IDH wild-type subtype—who can provide tumor samples or be seen at a participating center would be the most relevant candidates for related future studies.
Not a fit: Patients with non-glioblastoma brain tumors, with IDH-mutant gliomas, or those unable to provide tissue or attend the study center are less likely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this work could identify a new way to make glioblastoma stem cells more sensitive to radiation and other treatments, potentially lowering recurrence.
How similar studies have performed: Previous laboratory studies have linked Lucat1 and other long non-coding RNAs to worse glioblastoma outcomes, but targeting lncRNAs in patients remains largely experimental.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Yu, Jennifer S — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Yu, Jennifer S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.